Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib + Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
NCT04878029Phase 1Recruiting
- Sponsor
- Emory University
- Start
- Jul 2021
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cabozantinib in urothelial carcinoma (UC), sponsored by Emory University. Primary endpoint: Incidence of adverse events up to 5 years. Started Jul 2021; status: recruiting.
02
Drugs
cabozantinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04878029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04878029.